Advanced Diagnostic Laboratories

IgE Receptor Antibody (CD203)

Test Code

CD203

Description

The test detects functional autoantibodies to the Fc-epsilon receptor (high affinity IgE receptor) or autoantibodies to IgE and is useful in the evaluation of chronic urticaria.

Collect

One 4 mL Serum Separator Tube or 4 mL Red top tube.

Patient Prep

Separate serum from cells by centrifugation and aliquot into a polypropylene or similar plastic tube.

Pediatric Collection

Minimum volume: 0.5 mL

Unacceptable Conditions

Grossly hemolyzed specimens

Storage Transport Temp

Frozen. Send serum Priority Overnight via FedEx and in a well insulated container on dry ice.

Stability

48 hours ambient. 7 days refrigerated, 1 year at -20°C or below. Avoid repeated freeze-thaw cycles.

Performed

Weekly

Methodology

Flow Cytometry

Turnaround Time

7-9 business days

Department

Immunology Lab - Diagnostic

Synonyms

Chronic Urticaria (Anti-IgE Receptor Ab), FC Epsilon (Anti-IgE Receptor Ab), CU (Anti-IgE Receptor Ab), Hives (Anti-IgE Receptor Ab), Urticaria (Anti-IgE Receptor Ab), CD203c (Anti-IgE Receptor Ab), Basophil Degranulation assay (Anti-IgE Receptor Ab), IGERAB (Anti-IgE Receptor Ab), IGERAB, CD203c, Basophil Degranulation, BHR, CD203a

Study Offerings

RUO
CAP/CLIA

Reference Interval

<=12%

Interpretation

Chronic autoimmune urticaria (CIU) may be associated with autoantibodies to the high affinity lgE receptor (Fe-epsilon R1) or to lgE. In the presence of these autoantibodies, cross-linking of the Fc-epsilon-R1 receptor occurs, leading to basophil activation. The laboratory tests for the activation of donor basophils by CIU serum by analyzing the expression of the basophil specific ectoenzyme, CD203c. CD203c is upregulated on the surface of basophils following activation. A positive result is indicative of the presence of autoantibodies associated with CIU, but may also be due to other basophil-activating serum factors. Results must be correlated with clinical findings. The reference range was developed by the National Jewish Health Advanced Diagnostic Laboratories by analyzing 80 healthy control serum samples.